Shares of Cempra, Inc. (NASDAQ:CEMP) have received an average rating of “Hold” from the twenty research firms that are presently covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $8.85.

Several research firms have weighed in on CEMP. Jefferies Group LLC restated a “hold” rating and set a $3.00 target price on shares of Cempra in a report on Thursday, May 25th. Roth Capital downgraded shares of Cempra from a “buy” rating to a “neutral” rating and dropped their target price for the company from $8.00 to $4.00 in a report on Thursday, August 10th. Stifel Nicolaus restated a “hold” rating and set a $4.00 target price on shares of Cempra in a report on Thursday, August 10th. Zacks Investment Research downgraded shares of Cempra from a “buy” rating to a “hold” rating in a report on Monday, August 14th. Finally, Vetr upgraded shares of Cempra from a “buy” rating to a “strong-buy” rating and set a $4.86 price target for the company in a report on Monday, May 1st.

Several large investors have recently added to or reduced their stakes in the company. State Street Corp boosted its stake in Cempra by 85.8% in the fourth quarter. State Street Corp now owns 2,133,275 shares of the biotechnology company’s stock valued at $5,973,000 after buying an additional 985,427 shares in the last quarter. Guggenheim Capital LLC bought a new stake in Cempra during the fourth quarter valued at about $560,000. Norges Bank bought a new stake in Cempra during the fourth quarter valued at about $743,000. Teachers Advisors LLC boosted its stake in Cempra by 5.2% in the fourth quarter. Teachers Advisors LLC now owns 93,481 shares of the biotechnology company’s stock valued at $262,000 after buying an additional 4,632 shares in the last quarter. Finally, Bank of Montreal Can boosted its stake in Cempra by 187.8% in the first quarter. Bank of Montreal Can now owns 113,933 shares of the biotechnology company’s stock valued at $428,000 after buying an additional 74,343 shares in the last quarter. 52.39% of the stock is currently owned by institutional investors and hedge funds.

Cempra (CEMP) opened at 2.85 on Tuesday. The company’s 50-day moving average is $3.92 and its 200 day moving average is $3.84. The stock’s market capitalization is $149.64 million. Cempra has a one year low of $2.55 and a one year high of $26.95.

Cempra (NASDAQ:CEMP) last posted its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.23) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.09. Cempra had a negative net margin of 560.40% and a negative return on equity of 53.99%. The firm had revenue of $0.86 million during the quarter, compared to the consensus estimate of $3.58 million. During the same period last year, the firm posted ($0.51) EPS. The firm’s revenue for the quarter was down 74.9% on a year-over-year basis. Equities analysts expect that Cempra will post ($1.01) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Cempra, Inc. (CEMP) Given Consensus Rating of “Hold” by Analysts” was first published by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.americanbankingnews.com/2017/08/22/cempra-inc-cemp-given-consensus-rating-of-hold-by-analysts.html.

About Cempra

Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).

Analyst Recommendations for Cempra (NASDAQ:CEMP)

Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.